Verve Therapeutics Surges Premarket on Verve-102 Study Data

Dow Jones

Apr 14, 2025

By Colin Kellaher

Verve Therapeutics shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines company reported positive early study data for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis.

Shares of the Boston company, which closed Friday at $3.26, were recently up 45% to $4.74.

Verve said Verve-102 was well-tolerated among 14 participants across three dose levels in a Phase 1b study in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed.

Verve-102 is designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces low-density lipoprotein cholesterol, or LDL-C.

Verve said a single infusion of Verve-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.

Verve on Friday said the U.S. Food and Drug Administration granted fast-track designation to Verve-102.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 14, 2025 08:08 ET (12:08 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2527773152"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527773152\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527773152?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-14 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527773152","market":"other","top_or_hot":-1,"title":"Verve Therapeutics Surges Premarket on Verve-102 Study Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VERV\">Verve Therapeutics</a> shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines company reported positive early study data for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis. \n</p>\n<p>\n  Shares of the Boston company, which closed Friday at $3.26, were recently up 45% to $4.74. \n</p>\n<p>\n  Verve said Verve-102 was well-tolerated among 14 participants across three dose levels in a Phase 1b study in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed. \n</p>\n<p>\n  Verve-102 is designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces low-density lipoprotein cholesterol, or LDL-C. \n</p>\n<p>\n  Verve said a single infusion of Verve-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. \n</p>\n<p>\n  Verve on Friday said the U.S. Food and Drug Administration granted fast-track designation to Verve-102. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2025 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verve Therapeutics Surges Premarket on Verve-102 Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerve Therapeutics Surges Premarket on Verve-102 Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-14 20:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VERV\">Verve Therapeutics</a> shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines company reported positive early study data for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis. \n</p>\n<p>\n  Shares of the Boston company, which closed Friday at $3.26, were recently up 45% to $4.74. \n</p>\n<p>\n  Verve said Verve-102 was well-tolerated among 14 participants across three dose levels in a Phase 1b study in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed. \n</p>\n<p>\n  Verve-102 is designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces low-density lipoprotein cholesterol, or LDL-C. \n</p>\n<p>\n  Verve said a single infusion of Verve-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. \n</p>\n<p>\n  Verve on Friday said the U.S. Food and Drug Administration granted fast-track designation to Verve-102. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2025 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2527773152","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527773152","pubTimestamp":1744632480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verve Therapeutics shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines company reported positive early study data for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis.Shares of the Boston company, which closed Friday at $3.26, were recently up 45% to $4.74.Verve-102 is designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces low-density lipoprotein cholesterol, or LDL-C.Verve said a single infusion of Verve-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.Verve on Friday said the U.S. Food and Drug Administration granted fast-track designation to Verve-102.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VERV":"Verve Therapeutics","BK4539":"次新股"},"translate_title":"Verve Therapeutics因Verve-102研究数据上市前股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERV":1},"content_text":"By Colin Kellaher \n\n\n \n\n\nVerve Therapeutics shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines company reported positive early study data for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis. \n\n\n  Shares of the Boston company, which closed Friday at $3.26, were recently up 45% to $4.74. \n\n\n  Verve said Verve-102 was well-tolerated among 14 participants across three dose levels in a Phase 1b study in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed. \n\n\n  Verve-102 is designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces low-density lipoprotein cholesterol, or LDL-C. \n\n\n  Verve said a single infusion of Verve-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. \n\n\n  Verve on Friday said the U.S. Food and Drug Administration granted fast-track designation to Verve-102. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2025 08:08 ET (12:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}